How long does it take for resistance to Capmatinib/Tourad to appear?

Capmatinib (Capmatinib) is a targeted drug targeting MET exon 14 skipping mutations and is used to treat non-small cell lung cancer (NSCLC). Unlike traditional chemotherapy drugs, capmatinib can produce a highly selective effect on cancer cells by targeting specific gene mutations. However, resistance to any targeted therapy may develop after long-term use, and capmatinib is no exception.

Drug resistance refers to changes in tumor cells through genetic mutations or other biological mechanisms after drug treatment, making the drug ineffective. For capmatinib, the development of resistance generally depends on several factors, including tumor type, individual patient differences, duration of treatment, and the presence of new mutations or genetic alterations.

1. Resistance mechanism: Studies have shown that resistance to capmatinib is usually due to the further development ofMET gene mutations. For example, additional mutations in the MET gene (such as MET amplification or secondary mutations) may lead to changes in the target, making capmatinib unable to effectively bind and inhibit the MET receptor. Therefore, resistance usually occurs after a few months or a year of treatment, but some patients can tolerate longer treatment.

2. Manifestations of drug resistance: Once a patient develops drug resistance, he or she will usually show signs of worsening of the condition, such as rapid tumor progression, changes in imaging examinations, or aggravation of symptoms. If the drug is found to be less effective, doctors may confirm drug resistance by testing blood or tumor markers, imaging scans, and more.

3. Response after drug resistance: Once drug resistance occurs, doctors usually consider changing treatment strategies, such as using other targeted drugs, or combining chemotherapy, immunotherapy and other treatment methods. On an individual basis, treatment options will vary based on the patient's type of drug resistance and treatment needs.

In conclusion, the time to onset of capmatinib resistance varies between patients and tumors. Drug resistance issues need to be managed through regular check-ups, monitoring of efficacy, and adjustments to treatment regimens.

Keyword tags: capmatinib,Capmatinib, drug resistance, MET gene mutation, non-small cell lung cancer, targeted therapy, drug resistance, treatment monitoring, tumor treatment

Reference materials:https://ec.europa.eu/health/documents/community-register/2022/20220620155859/anx_155859_en.pdf